LIDE’s CRO foundation is in traditional in-vivo studies, providing standard in-vivo efficacy platforms like CDX and PDX. Years of innovation and a penchant for using the latest technologies has resulted in novel LIDE offerings also.
| Technology | Purpose | Why LIDE |
| PDX – Patient Derived Xenograft | Gold standard for IND filing – 89% correlation with clinical response | Over 1600 LIDE PDX models, many with rare gene alterations or drug resistance |
| MiniPDX® | Novel, more cost-effective alternative to PDX with faster turnaround time, but still well correlated with PDX results and clinical response | LIDE has optimized its MiniPDX® technologies for years, with several supporting papers and currently running a RWE study in China |
| CDX – Cell-line Derived Xenograft | Traditional pre-cursor to PDX – only 5% correlation with clinical response | Over 50 LIDE CDX models, |
| CRC – Conditionally Reprogrammed Cells | Novel alternative to commercialized cell lines to maintain heterogeneity, to increase correlation with clinical results | LIDE has years of experience working with CRCs to expand cell cultures from patient tissue samples for in-vivo studies |
LIDE’s Functional Diagnosis platform offers drug companies a more efficient pathway to successful clinical trials.
Learn more about Functional Diagnosis
LIDE’s IO platform leverages HuPBMC reconstituted or co-inoculated (with commercialized cell line or PDX cell suspension) models established from CDXs or PDXs.
Learn more about LIDE's IO platform
Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform